Product Pipeline: ONC-392

CTLA-4 was commercially validated as the first target to correct immune defects in cancer patients through antibody-based immunotherapy. However, CTLA-4-targeting drugs currently in clinical use cause immunotherapy-related adverse events (irAE) in 75-90% of cancer patients. The laboratory of Drs. Liu and Zheng established that the cancer immunotherapeutic effect (CITE) and irAE are mediated by distinct mechanisms and thus can be uncoupled through engineering of antibodies with stronger CITE but minimal irAE.

ONC-392 is such an antibody that targets CTLA-4 in a unique way to selectively eliminate tumor-infiltrating regulatory T cells (Treg) without affecting T cell activation in the peripheral T cells. Compared with other commercial and clinical stage anti-CTLA-4 antibodies, ONC-392 has more robust CITE but dramatically lower irAE. A Phase 1A/1B clinical trial to assess the safety, pharmacokinetics, and efficacy of ONC-392 as a single agent in advanced solid tumors and in combination with anti-PD(L)1 standard of care in Non- Small Cell Lung Cancer.



References

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, Zheng P, Liu Y. Cell Res. 2019 Aug;29(8):609-627. doi: 10.1038/s41422-019-0184-1. Epub 2019 Jul 2. How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity? Liu Y, Zheng P. Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/j.it.2018.10.009.

Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice.
Du X, Liu M, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, Zheng P. Cell Res. 2018 Apr;28(4):433-447. doi: 10.1038/s41422-018-0012-z. Epub 2018 Feb 20.

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P, Liu Y.
Cell Res. 2018 Apr;28(4):416-432. doi: 10.1038/s41422-018-0011-0. Epub 2018 Feb 22.

Human CTLA-4-knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P, Liu Y. Blood. 2005 Nov 1;106(9):3127-33. Epub 2005 Jul 21.

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.